-

Agilent to Participate in 9th Annual Evercore Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in the upcoming 9th Annual Evercore Healthcare Conference. Agilent management is scheduled to participate in a fireside chat from 10 a.m. to 10:50 a.m. EST on Tuesday, Dec. 1, 2026, in Coral Gables, Florida. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

INVESTOR CONTACT:
Tejas Savant
+1 917-574-4018
tejas.savant@agilent.com

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
christian.colon@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

INVESTOR CONTACT:
Tejas Savant
+1 917-574-4018
tejas.savant@agilent.com

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
christian.colon@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow. The introduction of Su...

Agilent Completes Acquisition of Proscia

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact...

Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the 5987A single quadrupole mass selective detector (MSD) with GC Assist, along with MassHunter 14 software. When combined with the Agilent 8890B or 8860B gas chromatograph, the 5987A creates an integrated GC/MS system designed to help laboratories improve data quality, reduce unplanned downtime and operate more efficiently. The 5987A delivers up to a 25% increase in scan rate while maintaini...
Back to Newsroom